News - Page 196 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article IntelGenx Announces Strategic Partnership with atai Life Sciences and Proposed TSX Graduation

IntelGenx Announces Strategic Partnership with atai Life Sciences and Proposed TSX Graduation

Post published:March 15, 2021
Post category:Press Release

Read more about the article MINDCURE Names Tarik Lebbadi as Chief Operating Officer

MINDCURE Names Tarik Lebbadi as Chief Operating Officer

Post published:March 15, 2021
Post category:Press Release

Read more about the article Mindset Pharma Files a Sixth U.S. Provisional Patent, Further Expanding Its Psychedelic Drug Candidates Pipeline With Novel DMT & 5-MeO-DMT Analogs

Mindset Pharma Files a Sixth U.S. Provisional Patent, Further Expanding Its Psychedelic Drug Candidates Pipeline With Novel DMT & 5-MeO-DMT Analogs

Post published:March 15, 2021
Post category:Press Release

Numinus Wellness Inc. Announces Upsized Bought Deal Public Offering to $35 million

Post published:March 15, 2021
Post category:Press Release

Numinus Wellness Inc. Announces $30 Million Bought Deal Public Offering

Post published:March 15, 2021
Post category:Press Release

Read more about the article Psychedelic Bulletin: Harvard Revisits Psychedelics; MindMed Attracts Strategic Investor; Psychedelics Companies Shed Cannabis Assets

Psychedelic Bulletin: Harvard Revisits Psychedelics; MindMed Attracts Strategic Investor; Psychedelics Companies Shed Cannabis Assets

Post published:March 12, 2021
Post category:Psychedelic Bulletin

Read more about the article Aion Therapeutic Files 4 New Patent Applications (Including for the Treatment of Human Cancers)

Aion Therapeutic Files 4 New Patent Applications (Including for the Treatment of Human Cancers)

Post published:March 11, 2021
Post category:Press Release

Read more about the article Octarine Bio announces closing of extended seed round financing of $1.2 million USD with an uptick in valuation due to significant investor demand.

Octarine Bio announces closing of extended seed round financing of $1.2 million USD with an uptick in valuation due to significant investor demand.

Post published:March 11, 2021
Post category:Press Release

Read more about the article BetterLife Subsidiary, Altum Pharmaceuticals, to Conduct Randomized Placebo-controlled COVID-19 Trial Using AP-003

BetterLife Subsidiary, Altum Pharmaceuticals, to Conduct Randomized Placebo-controlled COVID-19 Trial Using AP-003

Post published:March 11, 2021
Post category:Press Release

Read more about the article NeonMind Engages Certara to Advance its Synthetic Psilocybin Drug Candidates for Obesity

NeonMind Engages Certara to Advance its Synthetic Psilocybin Drug Candidates for Obesity

Post published:March 11, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.